Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Down 10.3% – What’s Next?

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) fell 10.3% during mid-day trading on Monday . The company traded as low as $48.45 and last traded at $48.45. 200 shares were traded during trading, a decline of 95% from the average session volume of 3,780 shares. The stock had previously closed at $54.00.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on ZLDPF shares. Cantor Fitzgerald reiterated a “neutral” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. William Blair reaffirmed a “market perform” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. Finally, BNP Paribas Exane lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 6th. Three research analysts have rated the stock with a Strong Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy”.

Zealand Pharma A/S Price Performance

The company has a current ratio of 23.57, a quick ratio of 23.57 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $3.44 billion, a price-to-earnings ratio of 3.57 and a beta of 0.87. The company’s 50 day moving average is $45.92 and its 200-day moving average is $62.02.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.37) by $0.50. Zealand Pharma A/S had a return on equity of 41.50% and a net margin of 68.82%.The firm had revenue of $5.33 million for the quarter, compared to analyst estimates of $2.81 million. Equities research analysts anticipate that Zealand Pharma A/S will post 2.95 earnings per share for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.